Clinical trials: Bloodstream Infections
West Nile Fever
Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
The purpose of this study is to determine whether a single subcutaneous injection of ChimeriVax-WN02 vaccine is well tolerated, safe and induces protective antibodies against West Nile Disease.
- Trial name
- NCT00442169
- Testing
- ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose
- Where
- 5 sites in United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Bacteremia, Staphylococcal Infection
MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial
In-vitro identification of S. aureus, methicillin-sensitive S. aureus (MSSA), and methicillin-resistant S. aureus (MRSA) from positive blood cultures by MicroPhage's bacteriophage-based diagnostic platform.
- Conditions
- Bacteremia, Staphylococcal Infection, Sepsis, Infection
- Trial name
- NCT00814151
- Testing
- MicroPhage S. aureus / MSSA / MRSA Blood Culture Test (prototype)
- Where
- 3 sites in United States
- Volunteers
- 712 people
- Sponsor
- MicroPhage, Inc.
Biomarkers, Acute Kidney Injury
Vancomycin Exposure and Biomarker Tracking Using Real-time Monitoring of Interstitial Fluid
The goal of this observational study is to understand whether a wearable sensor (the Nutromics Sensor Device) can accurately measure drug and biomarker levels in the fluid just under the skin (interstitial fluid), instead of…
- Conditions
- Biomarkers, Acute Kidney Injury, Sepsis
- Trial name
- VENTURE (NCT07893223)
- Where
- 5 sites in United States
- Volunteers
- 200 people
- Sponsor
- Nutromics
Severe Sepsis
Symphony IL-6 Cutoff Validation Study for Patients at Risk of Severe Sepsis
Symphony IL-6 is a device that quantitates human IL-6 by fluorescence enzyme immunoassay (FEIA) from whole-blood specimens. Use of Symphony IL- 6 removes the need for plasma separation before testing.
- Trial name
- NCT05048927
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Bluejay Diagnostics, Inc.
Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP)
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections
The study will evaluate the efficacy and safety of Meropenem and Pralurbactam versus Best Available Therapy in the treatment of Carbapenem-Resistant Enterobacteriaceae Infections.
- Conditions
- Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP), Complicated Intra-abdominal Infection (cIAI), Complicated Urinary Tract Infection (cUTI)
- Trial name
- NCT07089186
- Testing
- Meropenem and Pralurbactam, Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Sepsis, Respiratory Failure
Safety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis
This is a prospective, multinational, multicentre, randomised, parallel-group, open-label study to assess the safety, tolerability and performance of the NucleoCapture extracorporeal apheresis device in the reduction of…
- Trial name
- NUC-CAP (NCT05647096)
- Testing
- NucleoCapture device
- Where
- 9 sites in Germany, Switzerland and 1 more
- Volunteers
- 73 people
- Sponsor
- Santersus AG
Plague, Plague, Bubonic
Yersinia Pestis Lateral Flow Immunoassay for Blood Samples
Plague is a deadly but highly treatable disease caused by the bacterium Y. pestis. Due to the historical development of Y. pestis as a bioweapon by several nation states, it is listed by the US as a potential bioweapon that could…
- Conditions
- Plague, Plague, Bubonic, Plague, Pneumonic, Yersinia Pestis Plague
- Trial name
- SMARTPRT (NCT04688996)
- Testing
- Lateral Flow Assay for Pathogens of the Plague
- Where
- 2 sites in United States, Madagascar
- Volunteers
- 500 people
- Sponsor
- Brimrose Technology Corporation
Septic Shock, Endotoxemia
Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19
Prospective, observational, clinical investigation of PMX cartridge use in COVID 19 patients with septic shock
- Conditions
- Septic Shock, Endotoxemia, COVID, Corona Virus Infection
- Trial name
- NCT04352985
- Testing
- Toraymyxin PMX-20R (PMX Cartridge)
- Where
- 3 sites in United States
- Sponsor
- Spectral Diagnostics (US) Inc.
Sepsis, Severe Sepsis
Machine Learning Sepsis Alert Notification Using Clinical Data
Machine learning is a powerful method to create clinical decision support (CDS) tools, when training labels reflect the desired alert behavior.
- Conditions
- Sepsis, Severe Sepsis, Septic Shock
- Trial name
- HindSight P2 (NCT04005001)
- Testing
- HindSight, InSight
- Where
- 3 sites in United States
- Volunteers
- 37,986 people, healthy volunteers welcome
- Sponsor
- Dascena
Catheter-Related Infections
Open-Label Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to < 18 Years of Age
This study is a post-marketing approval requirement to assess the safety and time to Catheter-related Bloodstream Infections (CRBSI) of DefenCath in pediatric population (birth to less than 18 years of age) who are on chronic HD…
- Trial name
- NCT06714864
- Testing
- (taurolidine and heparin) catheter lock solution, Standard of Care
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- CorMedix Therapeutics
Fatigue, End Stage Renal Disease (ESRD)
Lipid Infusion in Dialysis Patients With Endotoxemia
The purpose of this study is to determine whether a phospholipid emulsion is effective in the treatment of chronic endotoxemia in hemodialysis patients.
- Trial name
- LIPIDOSE (NCT00506454)
- Testing
- Lipidose
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Sepsicure
Sepsis, Septic Shock
An Algorithm Driven Sepsis Prediction Biomarker
A sepsis early warning predictive algorithm, InSight, has been developed and validated on a large, diverse patient cohort. In this prospective study, the ability of InSight to predict severe sepsis patients is investigated.
- Conditions
- Sepsis, Septic Shock, Severe Sepsis
- Trial name
- NCT03015454
- Testing
- Severe Sepsis Prediction, Severe Sepsis Detection
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Dascena
Bacteremia
Prospective Study Into the Performance of the MicroPhage S. Aureus/MSSA/MRSA Test Direct From Blood Culture Positives
Direct in-vitro identification of S. aureus, methicillin-sensitive S. aureus (MSSA), and methicillin-resistant S. aureus (MRSA) from positive blood cultures by MicroPhage's bacteriophage-based diagnostic platform, two…
- Trial name
- NCT01184339
- Testing
- MicroPhage S. aureus/MSSA/MRSA Blood Culture Test
- Volunteers
- 1,165 people
- Sponsor
- MicroPhage, Inc.
Sepsis
Evaluation of the IB10 Sphingotest PCT+ in a Point-of-Care Setting
To establish the equivalence of IB10 sphingotest PCT+ measurements in point-of-care settings such as emergency rooms or intensive care units, with corresponding procalcitonin measurements obtained in a reference or clinical…
- Trial name
- NCT04529733
- Testing
- IB10 sphingotest PCT+
- Volunteers
- 300 people
- Sponsor
- Nexus DX
Late Onset Neonatal Sepsis, Necrotizing Enterocolitis
Effects of Oral Probiotic Supplementation on the Clinical Status of Very-low-birth-weight Preterm Neonates.
The purpose of this study was to evaluate the safety of a probiotic foodstuff and its influence on emergence and development of natural intestinal flora and the clinical status of premature very low birth weight neonates.
- Conditions
- Late Onset Neonatal Sepsis, Necrotizing Enterocolitis, Infant, Very Low Birth Weight
- Trial name
- NCT02073214
- Testing
- Probiotic
- Volunteers
- 182 people
- Sponsor
- IBSS Biomed S.A.
Sepsis, Renal Failure
The Prevention of Failure to Rescue Using Early Warning Scoring
The purpose of this study is to assess if, compared with standard paper-based systems, an automated Early Warning System (EWS) resident in a spot check patient monitor, can help to identify deteriorating patients.
- Conditions
- Sepsis, Renal Failure, Pulmonary Edema, Cardio-pulmonary Arrest
- Trial name
- VitalCare (NCT01197326)
- Testing
- use of the MP5 EWS patient monitor
- Where
- Australia
- Volunteers
- 414 people, healthy volunteers welcome
- Sponsor
- Philips Healthcare
Sepsis
Can Respiratory Rate Predict the Risk of Deterioration of Septic Patients
The primary objective is to determine if the trend in Respiratory Rate measurements provided by the device under investigation can be used to predict an increase in Sequential/Sepsis-related Organ Failure Assessment (SOFA) score.
- Trial name
- NCT03752047
- Where
- Denmark
- Volunteers
- 132 people
- Sponsor
- PMD Solutions
E.Coli Infections, Bloodstream Infection
A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose, dose escalation study in healthy participants, investigating the safety, tolerability, recovery, and PD of multiple oral administrations of SNIPR001.
- Trial name
- NCT05277350
- Testing
- SNIPR001
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- SNIPR Biome Aps.
Sepsis
Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation
SRT2379 is a potent small molecule activator of SIRT1 that has been found to inhibit systemic inflammation induced by intravenous injection of lipopolysaccharide (LPS) in mice.
- Trial name
- NCT01416376
- Testing
- SRT2379
- Where
- Netherlands
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Sirtris, a GSK Company
Septic Shock
Human Albumin Treatment in Adult Septic Shock. A Study Evaluating Immune Response and Organ Failure.
The goal of this phase 2, multicenter, randomized, controlled study is to evaluate the effect of albumin treatment on B cell and other immune cell gene exptression in adults with septic shock.
- Trial name
- ALBUMIM (NCT05645887)
- Testing
- Human albumin, Saline solution
- Sponsor
- Albimmune SL